131086-23-2Relevant academic research and scientific papers
4′-Modified Pyrimidine Nucleosides as Potential Anti-hepatitis C Virus (HCV) Agents
Shakya, Neeraj,Vedi, Satish,Liang, Chao,Agrawal, Babita,Kumar, Rakesh
, p. 917 - 921 (2014/07/21)
Herein, we have investigated novel pyrimidine nucleosides bearing a 4'-carboxyl functionality (6-10, 13 and 15) as anti-HCV agents. In this new class of compounds, 7, 9, 10 and 15 demonstrated in vitro anti-HCV activity similar to or better than a known anti-HCV drug, ribavirin. In this work, we also, surprisingly, identified a 3'-sulfoxide analog of 3′-thiacytidine (16), obtained as a side product during the synthesis of 15, as a potent inhibitor of HCV replication at the concentration similar to that of ribavirin. No detectable in vitro cytotoxicity was observed for the investigated compounds up to the highest concentration tested.
PROCESS FOR PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE
-
Page/Page column 12, (2011/11/30)
The present invention relates to a novel and stereoselective synthetic process for the preparation of optically active cis-nucleoside derivatives of compound of Formula (I), wherein R3 represents H, F, Cl, C1-16 alkyl.
PROCESS FOR THE PREPARATION OF CIS-NUCLEOSIDE DERIVATIVE
-
Page/Page column 32, (2010/08/08)
The present invention relates to a novel and stereoselective synthetic process for the preparation of optically active cis-nucleoside derivatives of compound of Formula (I), wherein R3 represents H, F, Cl, C1-16 alkyl.
2-Substituted-4-substituted-1,3-dioxolanes and use thereof
-
Page column 40, (2010/11/29)
Nucleoside analogues containing a 1,3-dioxolane structure are suitable antiviral agents, particulary for the treatment of the HIV infections in mammals, especially humans. Examples of the nucleoside analogues include: cis-2-acetoxymethyl-4-(thymin-1′-yl)-1,3,-dioxolane, cis-2-hydroxymethyl-4-(thymin-1′-yl)-1,3-dioxolane, cis-2-benzoyloxymethyl-4-(cytosin-1′-yl)-1,3-dioxolane, and cis-2-hydroxymethyl-4-(cytosin-1′-yl)-1,3-dioxolane. These compounds can be in the form of their racemates or their separate enantiomers.
